Alexandros Polydorides
Icahn School of Medicine at Mount Sinai
Appearances
- DateMay 7, 2023The pathogenesis of inflammatory bowel disease (IBD) involves crosstalk between genetic and microbial factors that influence immune reactions. Tofacitinib, a pan JAK-STAT inhibitor, is a small molecule indicated for the treatment of moderate-to-severe ulcerative colitis (UC)…
Presenter
Speakers
Icahn School of Medicine at Mount SinaiIcahn School of Medicine at Mount SinaiIcahn School of Medicine at Mount Sinai - DateMay 7, 2023The pathogenesis of inflammatory bowel disease (IBD) involves crosstalk between genetic and microbial factors that influence immune reactions. Tofacitinib, a pan JAK-STAT inhibitor, is a small molecule indicated for the treatment of moderate-to-severe ulcerative colitis (UC)…
Presenter
Speakers
University Hospitals LeuvenIcahn School of Medicine at Mount SinaiIcahn School of Medicine at Mount SinaiIcahn School of Medicine at Mount Sinai - DateMay 19, 2024Vedolizumab (VDZ) is a monoclonal antibody that targets the gut-homing receptor α4β7. Despite its widespread use as a frontline therapy for ulcerative colitis (UC) and Crohn’s disease, its mode of action (MOA) remains unclear…
Presenter
Speakers
University Hospitals LeuvenIcahn School of Medicine at Mount SinaiIcahn School of Medicine at Mount SinaiIcahn School of Medicine at Mount Sinai - DateMay 6, 2025This symposium will discuss three difficult diagnoses during neoplasia surveillance in patients with IBD: invisible, indefinite, and non-conventional dysplasia…
Moderator
Icahn School of Medicine at Mount Sinai
